Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Forecast for the Desmoid Tumors Market from 2024 to 2025?

In the previous years, the market size of desmoid tumors has seen robust growth. The market is projected to increase from $2.97 billion in 2024 to $3.18 billion in 2025, growing at a compound annual growth rate (CAGR) of 7.3%. The surge in growth during the historical period is due to improvements in medical imaging, advancements in genetic research and comprehension, innovations in surgical procedures, enhanced awareness and education, and patient advocacy.

What Is the Projected Market Size of the Desmoid Tumors Market?

The market size for desmoid tumors is envisaged to experience significant expansion in the coming years, with anticipated growth to $4.13 billion by 2029, showing a compound annual growth rate (CAGR) of 6.8%. This upward trend during the forecast period is deemed to be due to the advent of targeted treatments, personalized healthcare, wide-ranging global collaborations, novel therapy approvals, and an increased focus on the patient-centric approach. Key trends projected for the forecast period encompass improvements in treatment methodologies, precision-based medicine and biomarker identification, clinical trials and research undertakings, cross-disciplinary treatment groups, as well as patient advocacy and backing.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13228&type=smp

Who are the Major Competitors in the Desmoid Tumors Market Outlook?

Major companies operating in the desmoid tumors market report are Pfizer Inc., F.Hoffmann-La Roche Ltd., AbbVie Inc., Bayer AG, Novartis AG, Abbott Laboratories, Amgen Inc., Stryker Corporation, Genome And Company, Vertex Pharmaceuticals Incorporated, Eisai Limited, Beckman Coulter Inc., Incyte Corporation, Ipsen Biopharmaceuticals Inc., BeiGene Ltd., Janssen Biotech Inc., Ionis Pharmaceuticals Inc., Ayala Pharmaceuticals Inc., Blueprint Medicines Corporation, Xencor Inc., MacroGenics Inc., Debiopharm Group, Clovis Oncology Inc., Juno Therapeutics Inc., SpringWorks Therapeutics Inc., Loxo Oncology Inc., Mirati Therapeutics Inc., Iterion Therapeutics Inc., Recepta Pharmaceuticals Inc., Cellestia Biotech AG

What Is Fueling Growth in the Desmoid Tumors Market?

The escalating incidences of cancer are anticipated to boost the growth of the desmoid tumor market. The term ‘cancer’ refers to a range of diseases characterized by the abnormal and uncontrolled growth and spread of cells in the body. Such abnormal cells can infiltrate and damage surrounding tissues and organs. The global increase in cancer cases has stimulated the need for effective and advanced chemotherapeutic treatments, which is positively impacting the desmoid tumor market. As per the data released by the National Cancer Institute, a Federal government agency based in the US, it is projected that about 2,001,140 new cancer cases and 611,720 cancer-related deaths will occur in the US in May 2024. In 2022, nearly 20 million new cancer cases and 9.7 million cancer-related fatalities were recorded globally. The number of new annual cancer cases is forecasted to escalate to 29.9 million by 2040, with the number of cancer-related fatalities anticipated to reach 15.3 million. Hence, the increasing prevalence of cancer is propelling the expansion of the desmoid tumor market.

Desmoid Tumors Market Driver: Government Funding Fuels Desmoid Tumor Market Expansion via Investment in Research and Development

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=13228&type=smp

Which Desmoid Tumors Market Segments Are Growing the Fastest?

The desmoid tumors market covered in this report is segmented –

1) By Treatment: Surgery, Radiation Therapy, Anti-Inflammatory Medication, Hormone Therapy, Chemotherapy, Novel Molecular-Targeted Therapy, Other Treatments

2) By Diagnosis: Biopsy, Electron Microscopic Examination, Immunohistochemical Analysis, Other Diagnosis

3) By End-User: Hospitals And Clinics, Specialty Centers, Other End-Users

Subsegments:

1) By Surgery: Wide Excision, Minimally Invasive Surgery

2) By Radiation Therapy: External Beam Radiation Therapy, Stereotactic Body Radiation Therapy

3) By Anti-Inflammatory Medication: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Corticosteroids

4) By Hormone Therapy: Selective Estrogen Receptor Modulators (SERMs), Aromatase Inhibitors

5) By Chemotherapy: Traditional Chemotherapy Agents, Combination Chemotherapy

6) By Novel Molecular-Targeted Therapy: Tyrosine Kinase Inhibitors, Other Targeted Therapies

7) By Other Treatments: Watchful Waiting, Physical Therapy, Pain Management Strategies

Which Industry Trends Are Shaping the Future of the Desmoid Tumors Market?

Leading companies in the desmoid tumors market are in the race to create novel drugs such as nirogacestat to better serve their existing clients’ needs. The drug, nirogacestat, is an oral, small-molecule gamma-secretase inhibitor. SpringWorks Therapeutics Inc., a clinical-stage biopharmaceutical company in the US, announced in February 2023 that their new drug application (NDA) for nirogacestat for treating adults with desmoid tumors received approval and priority review from the U.S. Food and Drug Administration (FDA). It’s believed that nirogacestat operates by inhibiting the production of notch proteins, potentially leading to the demise of tumor cells. Desmoid tumors are known to produce high levels of notch protein, which is thought to stimulate their growth. Furthermore, nirogacestat offers a potentially enhanced treatment alternative for patients.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/desmoid-tumors-global-market-report

Which Countries Are Leading the Desmoid Tumors Market?

North America was the largest region in the desmoid tumors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the desmoid tumors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13228

This Report Delivers Insight On:

1. How big is the desmoid tumors market, and how is it changing globally?

2. Who are the major companies in the desmoid tumors market, and how are they performing?

3. What are the key opportunities and risks in the desmoid tumors market right now?

4. Which products or customer segments are growing the most in the desmoid tumors market?

5. What factors are helping or slowing down the growth of the desmoid tumors market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model